Kymera Therapeutics (KYMR) Stock May Be Overvalued Following Positive KT 579 Data
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116
Kymera (KYMR) Q3 2026 Earnings Call Transcript
Kymera Therapeutics Q3 Earnings Call Highlights
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
Kymera Therapeutics To Announce Results From Its Phase 1 Clinical Trial Evaluating Single And Multiple-Ascending Doses Of KT-579 In Healthy Volunteers On October 29
Kymera Therapeutics (KYMR) Nears Earnings With KT 621 In Focus, Is The Stock Still Cheap?
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon
Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140
Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.